Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Lymphoma 19Leukemia, Myeloid, Acute 18Myelodysplastic Syndromes 17Lymphoma, Non-Hodgkin 14Neoplasms, Plasma Cell 12Leukemia 12Neuroblastoma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Lymphoma, Large B-Cell, Diffuse 9Hodgkin Disease 9Recurrence 7Melanoma 7Lymphoma, Mantle-Cell 7Hematologic Neoplasms 7Burkitt Lymphoma 7Sarcoma 6Ovarian Neoplasms 6Myeloproliferative Disorders 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6Sarcoma, Ewing 5Neoplasm Metastasis 5Medulloblastoma 5Lymphoma, B-Cell, Marginal Zone 5Liver Neoplasms 5Wilms Tumor 4Rhabdomyosarcoma 4Retinoblastoma 4

Interventions

tremelimumab 3durvalumab 3Ipilimumab 3pembrolizumab 2Nivolumab 2Carboplatin 2poly ICLC 1osimertinib 1lenvatinib 1cemiplimab 1Vascular Endothelial Growth Factor A 1Vaccination 1Peptides 1Pemetrexed 1Paclitaxel 1Monophenol Monooxygenase 1Melphalan 1Docetaxel 1Axitinib 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Diabetes Mellitus, Insulin-Dependent, 12 × Melphalan × Clear all
NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Ludwig Institute for Cancer Research

Phase 1 Terminated
6 enrolled 11 charts
Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡